Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00955474 · ClinicalTrials.gov registry record · Phase 4

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

A Phase 4 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 4
Development phase
32
Enrollment target

NCT00955474: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.

NCT00955474 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00955474, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 4
Development phase
32 participants
Enrollment target

Study Summary

The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.

Interventions

  • DRUG Quetiapine
  • DRUG Sertraline
  • DRUG Citalopram
  • DRUG escitalopram

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2008-09
Est. Completion 2013-01
Phase Phase 4

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00955474

The ClinicalTrials.gov registry entry for NCT00955474 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Quetiapine is the first listed.

NCT00955474 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00955474 about?

NCT00955474 is a clinical study titled "Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms". The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.

What is the current status of trial NCT00955474?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2008-09. Estimated completion is 2013-01.

What interventions are being tested in trial NCT00955474?

The interventions under investigation include: Quetiapine (DRUG), Sertraline (DRUG), Citalopram (DRUG), escitalopram (DRUG).

Who is sponsoring clinical trial NCT00955474?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.